Masaru Obokata1, Yogesh N V Reddy1, Sanjiv J Shah2, David M Kaye3, Finn Gustafsson4, Gerd Hasenfuβ5, Elke Hoendermis6, Sheldon E Litwin7, Jan Komtebedde8, Carolyn Lam9, Daniel Burkhoff10, Barry A Borlaug11. 1. Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota. 2. Division of Cardiology, Northwestern University, Chicago, Illinois. 3. Baker IDI Heart and Diabetes Institute and Alfred Hospital, Melbourne, Victoria, Australia. 4. Department of Cardiology, Rigshospitalet, Copenhagen, Denmark. 5. Georg-August Universität, Heart Centre, Gottingen, Germany. 6. University Medical Center Groningen, Groningen, the Netherlands. 7. Medical University of South Carolina, Charleston, South Carolina. 8. Corvia Medical, Tewksbury, Massachusetts. 9. University Medical Center Groningen, Groningen, the Netherlands; National Heart Centre Singapore and Duke-National University of Singapore, Singapore; The George Institute for Global Health, Newtown, New South Wales, Australia. 10. Division of Cardiology, Columbia University, New York, New York. 11. Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota. Electronic address: borlaug.barry@mayo.edu.
Abstract
BACKGROUND: Implantation of an interatrial shunt device (IASD) in patients with heart failure (HF) reduces left atrial hypertension by shunting oxygenated blood to the right heart and lungs. The attendant increases in pulmonary blood flow (Qp) and oxygen content may alter pulmonary vascular function, while left-to-right shunting might compromise systemic perfusion. OBJECTIVES: The authors hypothesized that IASD would improve indexes of pulmonary artery (PA) function at rest and during exercise in HF patients without reducing systemic blood flow (Qs). METHODS: This is a pooled analysis from 2 trials assessing the effects of the IASD on resting and exercise hemodynamics in HF patients (n = 79) with EF ≥40% with baseline and repeated hemodynamic evaluation between 1 and 6 months. Patients with pulmonary vascular resistance (PVR) >4 WU or right ventricular dysfunction were excluded. RESULTS:Qp and PA oxygen content increased by 27% and 7% following IASD. These changes were associated with salutary effects on pulmonary vascular function (17% reduction in PVR, 12% reduction in PA elastance [pulmonary Ea], and 24% increase in PA compliance). Qp increased during exercise to a greater extent following IASD compared with baseline, which was associated with reductions in exercise PVR and pulmonary Ea. Patients with increases in PA compliance following IASD experienced greater improvements in supine exercise duration. There was no reduction in Qs following IASD at rest or during exercise. CONCLUSIONS: Implantation of an IASD improves pulmonary vascular function at rest and during exercise in selected patients with HF and EF ≥40%, without compromising systemic perfusion. Further study is warranted to identify underlying mechanisms and long-term pulmonary hemodynamic effects of IASD. (REDUCE LAP-HF Trial [REDUCE LAP-HF]; NCT01913613; and REDUCE LAP-HF Randomized Trial I [REDUCE LAP-HF I]; NCT02600234).
RCT Entities:
BACKGROUND: Implantation of an interatrial shunt device (IASD) in patients with heart failure (HF) reduces left atrial hypertension by shunting oxygenated blood to the right heart and lungs. The attendant increases in pulmonary blood flow (Qp) and oxygen content may alter pulmonary vascular function, while left-to-right shunting might compromise systemic perfusion. OBJECTIVES: The authors hypothesized that IASD would improve indexes of pulmonary artery (PA) function at rest and during exercise in HF patients without reducing systemic blood flow (Qs). METHODS: This is a pooled analysis from 2 trials assessing the effects of the IASD on resting and exercise hemodynamics in HF patients (n = 79) with EF ≥40% with baseline and repeated hemodynamic evaluation between 1 and 6 months. Patients with pulmonary vascular resistance (PVR) >4 WU or right ventricular dysfunction were excluded. RESULTS: Qp and PA oxygen content increased by 27% and 7% following IASD. These changes were associated with salutary effects on pulmonary vascular function (17% reduction in PVR, 12% reduction in PA elastance [pulmonary Ea], and 24% increase in PA compliance). Qp increased during exercise to a greater extent following IASD compared with baseline, which was associated with reductions in exercise PVR and pulmonary Ea. Patients with increases in PA compliance following IASD experienced greater improvements in supine exercise duration. There was no reduction in Qs following IASD at rest or during exercise. CONCLUSIONS: Implantation of an IASD improves pulmonary vascular function at rest and during exercise in selected patients with HF and EF ≥40%, without compromising systemic perfusion. Further study is warranted to identify underlying mechanisms and long-term pulmonary hemodynamic effects of IASD. (REDUCE LAP-HF Trial [REDUCE LAP-HF]; NCT01913613; and REDUCE LAP-HF Randomized Trial I [REDUCE LAP-HF I]; NCT02600234).
Authors: Chakradhari Inampudi; Daniel Silverman; Marc A Simon; Peter J Leary; Kavita Sharma; Brian A Houston; Jean-Luc Vachiéry; Francois Haddad; Ryan J Tedford Journal: Chest Date: 2021-08-12 Impact factor: 9.410
Authors: Yogesh N V Reddy; Masaru Obokata; Frederik H Verbrugge; Grace Lin; Barry A Borlaug Journal: J Am Coll Cardiol Date: 2020-09-01 Impact factor: 24.094
Authors: Wayne L Miller; Hidemi Sorimachi; Diane E Grill; Karen Fischer; Barry A Borlaug Journal: Eur J Heart Fail Date: 2021-02-21 Impact factor: 15.534
Authors: Bradley A Maron; Evan L Brittain; Edward Hess; Stephen W Waldo; Anna E Barón; Shi Huang; Ronald H Goldstein; Tufik Assad; Bradley M Wertheim; George A Alba; Jane A Leopold; Horst Olschewski; Nazzareno Galiè; Gerald Simonneau; Gabor Kovacs; Ryan J Tedford; Marc Humbert; Gaurav Choudhary Journal: Lancet Respir Med Date: 2020-07-27 Impact factor: 30.700